{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:34:31Z","timestamp":1760056471491,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.det.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:29:00Z","timestamp":1654190940000},"page":"265-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions"],"prefix":"10.1016","volume":"40","author":[{"given":"Melissa","family":"Reyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Kortepeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2005","series-title":"Guidance for industry: development and use of risk minimization action plans","key":"10.1016\/j.det.2022.02.002_bib3"},{"year":"2005","series-title":"Guidance for industry: good pharmacovigilance practice and pharmacoepidemiologic assessment","key":"10.1016\/j.det.2022.02.002_bib4"},{"issue":"3","key":"10.1016\/j.det.2022.02.002_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","article-title":"Cutaneous drug reactions","volume":"53","author":"Svensson","year":"2001","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.det.2022.02.002_bib6","first-page":"207","article-title":"Epidemiology of cutaneous drug-induced reactions","volume":"149","author":"Naldi","year":"2014","journal-title":"G\u00a0Ital Dermatol Venereol"},{"issue":"24","key":"10.1016\/j.det.2022.02.002_bib7","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.det.2022.02.002_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.det.2022.02.002_bib9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.281.9.824","article-title":"Postmarketing surveillance and adverse drug reactions: current perspectives and future needs","volume":"281","author":"Brewer","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.det.2022.02.002_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/9781119413431.ch10","article-title":"Postmarketing spontaneous pharmacovigilance reporting systems","author":"Dal Pan","year":"2019","journal-title":"Pharmacoepidemiology"},{"issue":"3","key":"10.1016\/j.det.2022.02.002_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaad.2010.05.033","article-title":"Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients","volume":"65","author":"Kothary","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2022.02.002_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2016.09.008","article-title":"Chemical leukoderma associated with methylphenidate transdermal system: data from the US Food and Drug Administration Adverse Event Reporting System","volume":"180","author":"Cheng","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.det.2022.02.002_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14740338.2020.1746267","article-title":"How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting","volume":"19","author":"Asfour","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.det.2022.02.002_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40268-020-00311-6","article-title":"Cutaneous adverse events in newly approved FDA non-cancer drugs: a systematic review","volume":"20","author":"Macklis","year":"2020","journal-title":"Drugs R D"},{"issue":"2","key":"10.1016\/j.det.2022.02.002_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.det.2022.02.002_bib16","first-page":"5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies","volume":"2018","author":"Ng","year":"2018","journal-title":"J\u00a0Immunol Res"},{"issue":"3 Pt 1","key":"10.1016\/j.det.2022.02.002_bib17","first-page":"458","article-title":"Guidelines of care for cutaneous adverse drug reactions. American Academy of Dermatology","volume":"35","author":"Drake","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2022.02.002_bib19","unstructured":"21CFR1.3 Definitions. April 2020. CFR - Code of Federal Regulations Title 21 (fda.gov). Accessed on April 12, 2021."},{"issue":"3","key":"10.1016\/j.det.2022.02.002_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/pds.3395","article-title":"Evaluation of FDA safety-related drug label changes in 2010","volume":"22","author":"Lester","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.det.2022.02.002_bib22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/pds.3317","article-title":"Post-market drug safety evidence sources: an analysis of FDA drug safety communications","volume":"21","author":"Ishiguro","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"21","key":"10.1016\/j.det.2022.02.002_bib25","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1001\/jama.1993.03500210065033","article-title":"Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems","volume":"269","author":"Kessler","year":"1993","journal-title":"JAMA"},{"journal-title":"Guidance Draft:","article-title":"Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff","year":"2019","key":"10.1016\/j.det.2022.02.002_bib26"},{"key":"10.1016\/j.det.2022.02.002_bib31","unstructured":"Importation of prescription drugs, final rule. Available at: Importation of Prescription Final Rule. Accessed March 31, 2021."},{"year":"2014","series-title":"Guidance for industry: E2B(R3) electronic transmission of individual case safety reports (ICSRs) implementation guide \u2013 data elements and message specification","key":"10.1016\/j.det.2022.02.002_bib33"},{"key":"10.1016\/j.det.2022.02.002_bib35","series-title":"Drug-induced liver toxicity. Methods in pharmacology and toxicology","article-title":"Postmarketing surveillance of drug-induced liver injury","author":"Jones","year":"2018"},{"issue":"2","key":"10.1016\/j.det.2022.02.002_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03256752","article-title":"MedDRA","volume":"23","author":"Mozzicato","year":"2009","journal-title":"Pharm Med"},{"issue":"6","key":"10.1016\/j.det.2022.02.002_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2022.02.002_bib40","doi-asserted-by":"crossref","unstructured":"Shah RR. Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics. Drug Saf - Case Rep 2017;11(4). https:\/\/doi.org\/10.1007\/s40800-017-0053-0.","DOI":"10.1007\/s40800-017-0053-0"},{"issue":"2","key":"10.1016\/j.det.2022.02.002_bib43","doi-asserted-by":"crossref","first-page":"pkab009","DOI":"10.1093\/jncics\/pkab009","article-title":"Risk of nonmelanoma skin cancer in association with use of hydrochlorothiazide-containing products in the United States","volume":"5","author":"Eworuke","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.det.2022.02.002_bib45","series-title":"Principles of clinical pharmacology","first-page":"455","article-title":"Chapter 27: Clinical analysis of adverse drug reactions","author":"Chamberlain","year":"2012"},{"key":"10.1016\/j.det.2022.02.002_bib46","unstructured":"Section 505(o)(4) of the FD&C Act. FD&C Act Chapter V: Drugs and Devices | FDA. Accessed March 31, 20 21."},{"year":"2013","series-title":"Guidance for industry: safety labeling changes \u2014 implementation of section 505(o)(4) of the FD&C Act","key":"10.1016\/j.det.2022.02.002_bib47"},{"year":"2006","series-title":"Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products \u2014 content and format","key":"10.1016\/j.det.2022.02.002_bib48"},{"year":"2011","series-title":"Guidance for industry: warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products \u2014 content and format","key":"10.1016\/j.det.2022.02.002_bib49"},{"year":"2012","series-title":"Guidance: drug safety information \u2013 FDA\u2019s communication to the public","key":"10.1016\/j.det.2022.02.002_bib50"},{"key":"10.1016\/j.det.2022.02.002_bib53","unstructured":"Do not use: black salve is dangerous and called by many names. Food and Drug Administration Web site. Published October 13, 2020. Accessed on March 12, 2021."},{"author":"Maddin","key":"10.1016\/j.det.2022.02.002_bib54"},{"issue":"11","key":"10.1016\/j.det.2022.02.002_bib55","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s40267-020-00775-1","article-title":"Cosmetic disfigurement from black salve","volume":"36","author":"Thambi","year":"2020","journal-title":"Drugs Ther Perspect"},{"issue":"5","key":"10.1016\/j.det.2022.02.002_bib59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjd.19504","article-title":"The value of case reports in pharmacovigilance","volume":"183","author":"Garcia-Doval","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2022.02.002_bib60","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2125.1996.tb00040.x","article-title":"Attitudes to adverse drug reaction reporting","volume":"41","author":"Inman","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.det.2022.02.002_bib61","article-title":"Making the Most of FDA\u2019s MedWatch","author":"Abelson","year":"2011","journal-title":"Rev Ophthalmol"},{"issue":"4","key":"10.1016\/j.det.2022.02.002_bib63","first-page":"417","article-title":"ASHP guidelines on adverse drug reaction monitoring and reporting","volume":"52","year":"1995","journal-title":"Am Soc Hosp Pharm"},{"issue":"6","key":"10.1016\/j.det.2022.02.002_bib64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2010.11.2233","article-title":"Improving the reporting of adverse drug reactions in the hospital setting","volume":"122","author":"Pushkin","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.det.2022.02.002_bib66","unstructured":"Berniker JS. Spontaneous reporting systems: achieving less spontaneity and more reporting. 2001."},{"key":"10.1016\/j.det.2022.02.002_bib67","doi-asserted-by":"crossref","unstructured":"Aronson JK. Case reports as evidence in pharmacovigilance. In: Mann's pharmacovigilance.2014:121-137.","DOI":"10.1002\/9781118820186.ch10"},{"issue":"6","key":"10.1016\/j.det.2022.02.002_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health Working Group","volume":"153","author":"Maverakis","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2022.02.002_bib69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjd.19677","article-title":"The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice","volume":"184","author":"Raschi","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2022.02.002_bib70","first-page":"190","article-title":"Monitoring Adverse Drug Events: The Food and Drug Administration MedWatch Reporting System","volume":"23","author":"Landow","year":"1998","journal-title":"Regional Anesthesia & Pain Medicine"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863522000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863522000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:01Z","timestamp":1760006701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863522000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0733863522000043"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2022.02.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}